Mark R. Hake

Mark R. Hake

CFA

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

Amwell Is a High-Priced Telehealth Stock With No Profits

By Mark R. Hake, CFA

Amwell is another high-priced telehealth stock with no profits. Avoid AMWL stock which trades at 24 times sales with no earnings prospects in the near term.

JFrog Is Still Wildly Overvalued Ahead of Insider Share Lockout Release

By Mark R. Hake, CFA

JFrog is still ridiculously overvalued ahead of its insider share lockout release. FROG stock is still trading for 29 times 2021 revenue forecasts, which is too high for most value investors.

Overvalued Alteryx Guides for Lower Revenue and Flat Earnings

By Mark R. Hake, CFA

Alteryx guides for lower revenue and flat earnings, leaving AYX stock overvalued. AYX stock is too high at 177 times earnings given that revenue and earnings are set to fall in Q4.

Nikola Will Likely Keep On Losing Money, Pushing NKLA Stock Lower

By Mark R. Hake, CFA

Nikola will likely keep on losing money, pushing NKLA stock lower. It is worth over 8 times less based on its negative cash flow.

Inovio Has Little to Show for Its Covid-19 Efforts

By Mark R. Hake, CFA

Inovio Pharmaceuticals has little to show for its Covid-19 efforts. INO stock is not worth more than $2, according to one short-seller.

As Its Free Cash Flow Perks up Nokia Stock Has Breakout Potential

By Mark R. Hake, CFA

Nokia stock is set to do extremely well as free cash flow rises. Nokia stock is likely to move substantially higher as FCF continues to make positive gains.

Hexo Stock Is a Losing Bet So Investors Should Short It

By Mark R. Hake, CFA

Hexo stock is a losing bet. Hexo stock won’t survive without further capital, providing investors a great shorting opportunity.

XPeng Might be at Full Value Unless Sales Surprise on the Upside

By Mark R. Hake, CFA

XPeng might be at full value unless sales surprise on the upside. XPEV stock trades at over 15 times estimated 2021 sales and looks fully valued here.

Golden Nugget Online Could Jump When Its Merger Closes with Landcadia

By Mark R. Hake, CFA

Golden Nugget Online could jump soon. When LCA stock merges with Golden Nugget Online at the end of this month, it could skyrocket.

Growing Free Cash Flow Could Boost Facebook Stock To $370

By Mark R. Hake, CFA

Facebook is still worth considerably more as its free cash flow gushes higher. FB stock is worth up to 35% more than current levels, and could hit $370 or beyond.

Load More